About the program
Program launch date: May 2022
Breast cancer is the leading cause of cancer-related deaths for women worldwide
Despite advances in diagnostic tools and therapies available, approximately 1 in 6 patients diagnosed with HR+/HER2- early breast cancer will experience disease recurrence within 5 years of treatment.
This expert-led program aims to improve the individualized management of HR+/HER2- early breast cancer through education on recurrence risk classification, current evidence-based guidelines, and new and emerging therapies.
There will also be guidance on integrating shared decision making into your practice drawing on insights from a patient on how best to communicate.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!